Dr Barry Kenny joins Heptares Therapeutics
This article was originally published in Scrip
Executive Summary
Heptares Therapeutics, a UK drug discovery company focused on G-protein-coupled receptor targets, has appointed Dr Barry Kenny chief business officer. He will focus on business development and strategic alliances, based on the company's drug discovery capabilities and its StaR technology. He has more than 24 years' research and management experience in the pharmaceutical and biotechnology industries, having most recently served as vice-president of drug discovery at Takeda Cambridge. Prior to that, he was commercial director at Paradigm Therapeutics.